CorMedix Inc. | |
Stock Exchange | NYSE |
EPS |
$1.18 |
Market Cap |
$218.85 M |
Shares Outstanding |
23.8 M |
Public Float |
102.13 M |
CorMedix Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
81.9 M |
Public Float |
78.13 M |
Address |
400 Connell Drive Berkeley Heights New Jersey 07921 United States |
Employees | - |
Website | http://www.cormedix.com |
Updated | 07/08/2019 |
CorMedix, Inc. operates as a pharmaceutical and medical device company that seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. |